A Strong Signal for Investors: VR LIFE and H2 Global Group Confirm the Value of Czech Innovations in MedTech Czech MedTech is no longer a fringe topic and is beginning to establish itself as a sector capable of combining technological innovation, clinical utility, and attractive value growth. It is precisely in this environment that H2 Global Group, a group focused on the development, clinical validation, and investment growth of healthcare technologies with international potential, is increasingly making its mark. One concrete proof that this approach works exceptionally well is the story of VR LIFE and its product, VR Vitalis.

In June 2023, H2 Investment, a subsidiary of H2 Global Group, entered VR LIFE with an investment of 15 million CZK in exchange for a 20% stake. Even then, it was an entry into a project with a strong technological foundation, clinical utility, and the ambition to scale its solutions beyond the domestic market. Today, this step demonstrates that a well-timed investment in medical technology can create significant value even before a potential strategic sale.

Another validating moment came in February 2026, when VR LIFE closed a “seed” investment round of €600,000, joined by investors such as Garage Angels and Electron CP. According to H2 Global Group materials, following this round, H2 Investment’s stake was diluted to 18.26%, but the implied value of this stake rose to approximately €1.278 million, or roughly 31.2 million CZK. This represents more than double the original investment. Although this is not a realized return, it is a clear signal that a well-chosen Czech MedTech project can be rapidly revalued at a higher valuation in its very next investment round.

The strength of this story does not rest solely on investment numbers, but primarily on the fact that VR LIFE has built a product with real-world applications in healthcare. VR Vitalis Pro is a certified medical device designed for patient rehabilitation in medical facilities. VR LIFE collaborates with institutions such as the University Hospital Ostrava, Rehabilitation Institute Hrabyně, AGEL Hospital Ostrava-Vítkovice, Darkov Spas, Beroun Rehabilitation Hospital, Malvazinky Rehabilitation Clinic, University Hospital Olomouc, Pavel Kolář Centre for Movement Medicine, or spa groups including Royal Spa and Priessnitz Medical Spa Jeseník. According to the company, the product is already deployed in over 40 healthcare facilities and private clinics.

A significant milestone was also winning the Company of the Year 2024 award in the Moravian-Silesian Region. Simultaneously, the company is developing its registration activities with the U.S. Food and Drug Administration (FDA) with the aim of entering the US market within the next few months. This exact combination of clinical utility, regulatory readiness, and foreign expansion is one of the reasons why such projects are becoming increasingly attractive to investors.

“For several years, I have dreamed of being able to help people all over the world while simultaneously building a strong and functional business model that confirms the viability of the entire system. Thanks to VR Vitalis and our unique solution, with which we are expanding abroad, this dream is gradually coming true,” says Jana Trdá, Ph.D., Founder of VR LIFE.

The fields of rehabilitation and neurorehabilitation are among the segments where digital health technologies make extraordinary sense. In a time of growing demand for care and staff shortages, solutions that increase the efficiency of care, patient motivation, and rehabilitation capacity are becoming a structural necessity. This is another reason why MedTech is increasingly interesting to investors today. Value in this segment is created not just in the product itself, but primarily in the combination of intellectual property, certification, clinical validation, regulatory readiness, and the ability to scale the solution across markets.

It is precisely within this logic that H2 Global Group’s next step must be viewed. The group is not only an investor in promising projects but is simultaneously developing its own technological and patent base through its subsidiary, H2 Medical Technologies. Part of the joint innovation framework between H2 Medical Technologies and the VR Vitalis project is also a unique, patent-pending solution that combines molecular hydrogen with virtual reality for lung rehabilitation. A utility model has already been drafted and a patent application filed for this technological combination. This step confirms that the group’s ambition is not merely to develop individual products, but to build a broader platform protected by intellectual property with the potential for further clinical validation and commercial use.

In this context, H2 Global Group as a whole comes into focus. The group is built on more than 19 years of research and development, European patent EP 3701956, and following approval by the State Institute for Drug Control (SÚKL) in January 2026, launched a clinical trial and the registration phase for the world’s first medical device utilizing molecular hydrogen through its subsidiary H2 Medical Technologies. With a current pre-money valuation of 1.6 billion CZK, the company operates with the ambition to reach a transaction value ranging from $0.5 to $1.5 billion USD, or approximately 11.5 to 34.5 billion CZK, within three years. Compared to the current valuation, this would represent a growth of approximately 600% to 2000%. For existing partners and incoming shareholders progressively entering the project, this is a very strong signal of future value development. Furthermore, the global market repeatedly confirms that strategic buyers are willing to pay very high amounts for quality healthcare technologies.

The potential of this area is further supported by more than 3,000 scientific publications focused on the use of molecular hydrogen in medicine, including over 150 human studies, which makes H2 Global Group a project with parameters that investors in medical technologies (MedTech) follow very closely. From a market perspective, it is not just another startup story, but a company that connects patent-protected technology, clinical advancement, regulatory progress, and investment growth potential.

“I have long been highly sensitive to the current state of healthcare, especially regarding children’s mental health, the quality of life of seniors, and people who are just gradually entering older age. These are some of the greatest societal challenges of our time, and it is no longer possible to ignore them. I am convinced that together with our international team, which connects top Japanese scientists and doctors with Czech experts, innovators, and other experts from abroad, we can offer the world sustainable, non-invasive, and functional solutions with a real impact on people’s quality of life. Our ambition is not just to develop new technologies, but to transform them into accessible innovations with long-term benefits for the whole of society. This approach is also embodied in our non-invasive hydrogen solution, which has future applications not only in the prevention and support of the treatment of Alzheimer’s dementia and mild cognitive impairment (MCI), but also across a wide spectrum of inflammatory processes in the body. It is exactly in these areas that medicine today is seeking new, safe, and functional ways to offer patients a higher quality of life, more effective long-term support, and, ultimately, a better and healthier society,” says David Maršálek, CEO and Founder of H2 Global Group.

The story of VR LIFE and the VR Vitalis product is therefore not just the success of a single company. For H2 Global Group, it represents concrete proof that a well-timed investment in Czech MedTech can bring not only strategic importance but also rapidly growing value. And that is exactly one of the most important signals for investors. Czech MedTech is showing today that even the domestic market can produce projects with clinical, international, and investment potential. H2 Global Group is among the companies that can not only recognize this trend but also actively co-create it.

Article Author David Maršálek – Editor-in-Chief of H2 Times News, the first hydrogen newspaper, and simultaneously the CEO and founder of H2 Global Group, which focuses on the development, clinical validation, and international scaling of healthcare technologies based on the use of molecular hydrogen, and on connecting capital with innovations in the medicine of the future.

www.H2invest.cz.

www.H2times.news.

www.MolekularniVodik.cz.

www.H2global.group

Source: https://www.penize.cz/tiskove-zpravy/487602-silny-signal-pro-investory-vr-life-a-h2-global-group-potvrzuji-hodnotu-ceskych-inovaci-v-medtechu

The world has entered a period of turbulence. Geopolitical and trade instability, pressure on healthcare systems, and an aging population are changing the rules of the game. Investors are no longer just looking for growth. They are looking for sectors that will be essential regardless of geopolitics, economic cycles, or market sentiment. And one of the strongest investment sectors today is MedTech – the medical technologies of the future.

The world has changed. And with it, the rules of investing.

The pressure on healthcare systems and the aging population show that a period is coming in which investors can no longer rely on traditional schemes. Looking for growth is not enough. It is necessary to look for resilience, social necessity, and fields that the world will need regardless of geopolitics, the economic cycle, or market sentiment.

That is precisely why more and more capital is starting to shift towards MedTech – the healthcare technologies of the future. It is a segment where social responsibility is exceptionally strongly combined with investment attractiveness. Health is not a trend. It is a certainty. And in turbulent times, even more so than ever before.

Treatment and Prevention as the New Safe Haven for Capital

Every period of uncertainty reveals what is truly indispensable to society: food, energy, water, and healthcare. However, healthcare itself is currently undergoing a fundamental transformation. Simply having more doctors, more hospitals, or more traditional care is no longer enough. The system is under pressure and will increasingly depend on technologies that can accelerate, streamline, and expand treatment, offering new possibilities where old approaches are no longer sufficient. At the same time, the importance of self-care, prevention, and personal responsibility for health outside the healthcare system itself will grow. The technologies of the future will not only play a role in hospitals and clinics but increasingly in people’s daily lives—through early intervention, support for regeneration, long-term care for cognitive and physical fitness, and reducing the pressure on an overburdened healthcare sector.

This is exactly why MedTech is ceasing to be a niche field and is becoming one of the most interesting investment themes of our time.

The European medical technology market is valued at approximately 170 billion euros, with over 38,000 companies operating within it, more than 90% of which are small and medium-sized enterprises (SMEs). In 2024 alone, more than 15,700 patent applications were filed in the sector. This is not a small segment for a few specialists. It is a strong innovation ecosystem where long-term value is created.

The United States sends an even stronger signal. The American medical technology market accounts for approximately 46% of global medical device sales, and it is there that the true value of successful medical innovation becomes apparent the fastest.

Billion-Dollar Deals Confirm MedTech is a Big Game

Today, investors only need to look at current transactions. Johnson & Johnson acquired Shockwave Medical for approximately $13.1 billion. Stryker took over Inari Medical for around $4.9 billion. Boston Scientific bought Axonics for $3.7 billion, Thermo Fisher acquired Olink for roughly $3.1 billion, and Zimmer Biomet bought Paragon 28 for about $1.2 billion. And there are many other similar transactions.

These numbers clearly show one thing: once a patent, clinical validation, regulatory clearance, and international growth potential are combined, assets are created for which strategic players pay billions. MedTech is no longer just the industry of the future. It is a market where big money is already moving today.

The Czech and Central European Markets Are Also Sending Strong Signals

The same trend is becoming increasingly visible in Central Europe. The Czech market no longer just creates startups without products. On the contrary: companies with certification, clinical relevance, international ambition, and real investment logic are emerging.

An example is Stimvia from Ostrava, which is developing neuromodulation technology and, after obtaining MDR (Medical Device Regulation) certification, is openly communicating its entry into the US with its URIS® system. The company works with the premise that for the diagnosis of overactive bladder alone, the direct and indirect costs of treatment in the EU and the US combined exceed $117 billion annually. This is exactly the type of market that interests investors: a large, expensive problem that has long been addressed inefficiently.

Another highly successful story is VR LIFE, whose product VR Vitalis Pro is an MDR-certified medical device for rehabilitation and neurorehabilitation in virtual reality. The company has already deployed its solution in healthcare facilities in the Czech Republic, Slovakia, Poland, and Ukraine. This means only one thing: it is not just an idea, but a real product with clinical and market application.

And it is right here that the investor story associated with H2 Investment, a company from the H2 Global Group, is very interesting.

The story of VR LIFE shows how quickly value is created in MedTech. H2 Investment entered the company in 2023 with an amount of 15 million CZK for a 20% stake. After an investment round in February 2026, the diluted share decreased to 18.26%, but according to the group’s materials, its value increased to approximately 1.278 million EUR, or about 31.2 million CZK. Even without an exit, the value of the investment grew by roughly 16.2 million CZK, or 108%. A model scenario is even more striking: if VR LIFE were to reach its planned valuation of 100 million EUR within a few years, H2 Investment’s stake would be worth approximately 18.26 million EUR, or about 446.2 million CZK. The original 15 million CZK would thus become a value higher by approximately 431.2 million CZK, representing an appreciation of around 2875%.

Czech HealthTech has already set a strong precedent. The uLékaře.cz project, co-founded by Tomáš Šebek, acquired a strategic buyer in the form of the Austrian healthcare group Mavie. Publicly available information speaks of a transaction worth upper hundreds of millions of crowns. This too is an important signal: Czech healthcare companies are starting to become attractive not only to domestic investors but also to foreign strategic partners.

Why H2 Global Group is Taking Center Stage

It is precisely in this light that H2 Global Group must be viewed. Not as just another startup story, but as a company entering MedTech at a time when the market already knows exactly what value patent-protected medical technology with clinical and regulatory progress can hold.

Building on over 19 years of research and development, H2 Global Group relies on the European patent EP 3701956 and, in January 2026, following approval by the State Institute for Drug Control (SÚKL), launched a clinical study through its subsidiary H2 Medical Technologies. Simultaneously, it entered the registration phase for the world’s first medical device utilizing molecular hydrogen. With a current pre-money valuation of 1.6 billion CZK, the company operates with the ambition of becoming an acquisition target for a strong international strategic partner within three years, with a potential transaction ranging from $0.5 to $1.5 billion, i.e., approximately 11.5 to 34.5 billion CZK. In other words: the company is aiming for a value corresponding to roughly 7 to 22 times its current valuation.

The reason why such an ambition may not be unrealistic is clear: today, the potential of molecular hydrogen is backed by more than 3,000 scientific publications and studies, including over 150 human studies, and H2 Global Group is simultaneously building not only a specific product but also a broader technological platform for the medicine of the future. The moment a patent, clinical results, registration, and international commercialization are combined, the company can move into the category of the most sought-after MedTech assets within a few years. In this segment, you don’t just pay for a finished product; you pay for a technological head start that is faster and cheaper to buy than to build from scratch. This is exactly why similar solutions at this stage are often sold to strategic players. The reason is not only capital appreciation but also the ability to accelerate registration, production, distribution, and entry into other global markets. Ultimately, it is often only a strong international partner that can transform a technological head start into global availability, bringing innovative solutions to a significantly larger number of patients they can genuinely help.

Capital is Already Shifting. The Question is, Who Will Be There

Today’s world is tougher, faster, less predictable, and significantly more demanding than it was a few years ago. But precisely such times also reveal which sectors carry real weight.

MedTech is one of them.

Billion-dollar transactions in the US, a robust European market, a growing number of patents, strong examples from Central Europe, and new Czech companies with clinical and technological ambitions all show one thing: capital is already starting to shift into the medicine of the future in a big way.

For investors who want more than just traditional sectors in their portfolio, this is a signal they shouldn’t ignore.

Because in turbulent times, the greatest value is not created where there is merely demand.

The greatest value is created where demand is inevitable.

And that is exactly why MedTech is becoming one of the strongest and most desirable investment themes of the coming years.

www.H2times.news www.MolekularniVodik.cz www.H2invest.cz

Author of the Article David Maršálek

Editor-in-Chief of H2 Times News, the first hydrogen newspaper, and also CEO and Founder of H2 Global Group.

About the Author

David Maršálek is the founder and owner of H2 Global Group, which focuses on the development, clinical validation, and international scaling of healthcare technologies based on the use of molecular hydrogen, as well as connecting capital with innovations in the fields of MedTech, HealthTech, Longevity, and long-term care. Under his leadership, the group acquired unique patent solutions from Japan, established cooperation with a top Japanese research team, built a technological and scientific base with a global reach, and achieved an announced pre-money valuation of 1.6 billion CZK. In January 2026, H2 Global Group launched a clinical study approved by SÚKL and simultaneously entered the registration phase for the world’s first medical device utilizing molecular hydrogen in the field of neurodegenerative diseases.

Source: https://www.penize.cz/tiskove-zpravy/487197-kam-perspektivne-investovat-v-dobe-turbulentni-nejistoty-chytry-kapital-miri-do-mediciny-budoucnosti

Czech start-ups are experiencing a significant investment boom, with an increasing share of capital flowing into medical projects. Investors are looking for technologies with global potential, strong intellectual property, clinical data, and a clear regulatory trajectory—factors that typically lead to a leap in valuation in MedTech. H2 Global Group, led by founder and CEO David Maršálek, is currently entering exactly this phase: the group is communicating a pre-money valuation of CZK 1.6 billion and is seeing growing interest from investors wanting to join the project.

MedTech is Back on Investors’ Radars

Healthcare innovations are among the most dynamic investment topics today. Global players in MedTech and HealthTech are actively seeking out the best technologies that are ready or close to market launch, not only through partnerships but also via equity investments and acquisition scenarios. This trend is also reflected in the Central European region, where clinically grounded platforms with international scalability are becoming targets for both investors and strategic partners, as they combine growth potential with significant societal impact.

H2 Global Group: From “Lower Hundreds of Millions” to CZK 1.6 Billion Pre-Money

Just a few years ago, the value of H2 Global Group hovered in the lower hundreds of millions of crowns. The turning point came when the group acquired and secured key intellectual property—namely the European patent EP 3701956 B1 “Prophylactic or therapeutic agent for dementia” from a Japanese research team led by Professor Shigeo Ohta—while simultaneously achieving regulatory and clinical milestones that are considered standard drivers for a leap in project valuation in the MedTech industry.

Video: https://www.youtube.com/watch?v=qgrEBbVWLdc

The patent describes the use of molecular hydrogen in the field of neurodegenerative diseases, including dementia, and is in the process of being expanded to other global territories. From an investment perspective, it is precisely this combination of a scientific foundation, patent protection, a regulatory plan, and clinical data that is crucial. Thanks to this combination, a “simple molecule” becomes a scalable technological platform that addresses not only economic but, more importantly, societal issues.

Another crucial step was the approval of a clinical study by the State Institute for Drug Control (SÚKL) and the transition into the clinical validation and registration phase of a medical device utilizing molecular hydrogen in the field of neurodegenerative diseases. It is the combination of securing patents, clinical trials, and subsequent regulatory steps that has led to the leap in valuation, as is customary in the MedTech sector.

Why Becoming Part of It Right Now Can Be Attractive for Investors

In MedTech, the largest portion of future value is often created when three elements converge: strong IP, clinical data, and regulatory feasibility. H2 Global Group is at this exact point: the clinical evaluation was announced as initiated in January 2026, and the project is simultaneously heading into the registration phase with the goal of registering the world’s first regulatory-approved medical device using molecular hydrogen.

For investors, this typically means:

• The opportunity to participate in the project before the full materialization of its clinical and regulatory value, i.e., at a time when the company’s value is typically much lower than it would be during a potential sale to a strategic partner.

• The chance to be part of a topic that is seeing growing demand not only from funds but also from strategic partners in the MedTech sector.

• The potential for future strategic agreements and acquisition scenarios, which are accelerating once again in the industry.

International “Appetite” for Unique Platform Solutions

From the perspective of global companies, it is crucial to acquire technology that is timeless, patent-protected, scalable, and regulatorily viable. It is precisely these types of projects that have become the subject of investments and acquisitions in recent years, as they accelerate the market introduction of innovations.

Evidence of this is the capital flow from strategic players in the MedTech space: for example, Johnson & Johnson acquired Shockwave Medical for approximately USD 13.1 billion, Novo Holdings took over Catalent for roughly USD 16.5 billion, and Siemens Healthineers acquired Varian Medical Systems for approximately USD 16.4 billion. Other frequently cited transactions include Philips and its purchase of BioTelemetry for roughly USD 2.8 billion or the acquisition of Abcam by Danaher for approximately USD 5.7 billion. This demonstrates that global players are actively purchasing technologies with clinical value, regulatory feasibility, and the potential for rapid scaling.

How Investors Can Get Involved

H2 Global Group is also targeting retail investors who want the opportunity to participate in a unique solution in the MedTech/HealthTech space. This opportunity is limited in both time and volume. Those interested in more information can write or call: David Konupčík, Director of Investor Relations Email: david.konupcik@H2invest.cz Tel.: +420 724 269 373, www.H2invest.cz, www.H2global.group, www.MolekularniVodik.cz

About the Author

David Maršálek is the founder and owner of H2 Global Group, which focuses on the development, clinical validation, and international scaling of medical technologies based on the use of molecular hydrogen, as well as connecting capital with innovations in MedTech, HealthTech, Longevity, and long-term care.

Under his leadership, the group acquired unique patent solutions from Japan, established cooperation with a top Japanese research team, built a technological and scientific base with a global reach, and increased the company’s value to a communicated pre-money valuation of CZK 1.6 billion. In January 2026, H2 Global Group launched a clinical study approved by SÚKL and simultaneously entered the registration phase for the world’s first medical device utilizing molecular hydrogen in the field of neurodegenerative diseases, with a clearly defined strategy of building the “medicine of the future” through a clinically and regulatorily grounded, scalable platform.

Source: H2 Global Group

Source: https://www.penize.cz/tiskove-zpravy/486211-investicni-boom-v-ceskem-medtech-h2-global-group-s-patentem-z-japonska-a-valuaci-16-mld-kc-pre-money-otevira-prostor

Forgetting your keys or an acquaintance’s name from time to time is human. However, if memory lapses occur more frequently, worsen, and begin to affect your daily life, it might be more than just “normal forgetting.” This is often where the boundary lies between normal aging and a condition experts call Mild Cognitive Impairment (MCI), which is frequently a precursor to Alzheimer’s dementia.

What is still normal forgetting, and what is not?

The brain changes as we age. Information retrieval slows down, and it takes us longer to recall names or specific words. This is natural. But warning signs look different:

• Repeatedly asking the same questions

• Getting lost in familiar places

• Difficulty with planning and organization

• Changes in personality or judgment

• Problems with common daily activities

If these symptoms persist, it could indicate early-stage cognitive impairment.

MCI: The Silent Precursor to Dementia

Mild Cognitive Impairment (MCI) represents an intermediate stage between normal, trouble-free aging and dementia.

People with MCI already experience a measurable decline in memory or other cognitive functions, but they can still maintain relative independence. Not every case of MCI inevitably leads to dementia, but the risk is significantly higher.

Scientific studies indicate that a certain proportion of patients with MCI will develop Alzheimer’s disease or another type of dementia within a few short years. That is exactly why early recognition is crucial.

How does dementia develop?

Dementia is not a single disease, but an umbrella term for a group of conditions that lead to the gradual loss of brain cells. In Alzheimer’s disease, the following occurs:

• Accumulation of pathological proteins (amyloid beta and tau protein)

• Damage to the connections between neurons (synapses)

• Gradual death of brain cells

• Shrinking of certain brain areas (especially the hippocampus—the memory center)

This process often begins many years before the first symptoms appear. This means that by the time significant memory issues arise, the disease may already be well advanced.

Why is early action important?

Early diagnosis allows for:

• Slowing progression through appropriate therapy

• Lifestyle adjustments (sleep, sufficient exercise, a nutritionally rich and balanced diet, mental activity)

• Planning for future care

• Involving family and support services

Breaking down the social stigma is also essential. We need to talk about cognitive disorders openly, without fear, and without prejudice.

Hope in Research and Innovations

Modern medicine is increasingly focusing on early detection and a preventive approach, followed by support for appropriate treatments. This exact idea is the foundation for the activities of the Czech company H2 Global Group, which has launched a globally unique study focused on innovative approaches to neurodegenerative diseases using molecular hydrogen.

The group’s founder, David Maršálek, has long emphasized that Alzheimer’s disease is not just an individual health problem, but a major societal challenge. Investments in research, prevention, and innovation are therefore not just a healthcare issue, but a matter of responsibility toward future generations.

Forgetting is not a weakness. It is a signal.

If you notice the aforementioned changes in yourself or your loved ones, do not ignore them. Consulting a general practitioner or neurologist can be a major turning point in your life.

Dementia does not start overnight. It often arrives silently, precisely during the MCI stage. And that is exactly when we have the greatest chance to actively influence our health. Because the sooner we act, the greater our hope of successfully maintaining a high-quality, fulfilling life for as long as possible.

Author: David Maršálek

About the author: David Maršálek is the founder and owner of the H2 Global Group, which focuses on the development, clinical validation, and international scaling of healthcare technologies based on the use of molecular hydrogen. He also bridges capital with innovations in MedTech, HealthTech, Longevity, and long-term care, including social services. Under his leadership, the group has acquired unique patent solutions from Japan, established cooperation with a top-tier Japanese research team, built a strong technological and scientific base with a global reach, and increased the company’s value to a pre-money valuation of CZK 1.6 billion.

In January 2026, H2 Global Group launched a clinical study approved by the State Institute for Drug Control (SÚKL) and simultaneously entered the registration phase for the world’s first medical device utilizing molecular hydrogen for neurodegenerative diseases. This was done with a clearly defined strategy to build the medicine of the future through a scalable technological platform that can be expanded into other areas of medicine. The group is thus moving into a phase considered a key value-creation point in MedTech, where clinical data and regulatory clearance typically lead to a leap in project valuation and increased interest from strategic partners. This is also why H2 Global Group is seeing growing interest from investors and entrepreneurs, both from the Czech Republic and abroad, who are looking to get involved in projects with global market potential and significant social impact.

David Maršálek has over 14 years of experience and expertise in molecular hydrogen and its practical applications in prevention for the general consumer public, as well as in the healthcare sector. He has built an international team of top experts—spanning from Japan through Europe to the USA—and his activities are geared toward future cooperation with global pharmaceutical and MedTech players. His goal is to introduce molecular hydrogen into regulated healthcare as part of “the medicine of the future” through a clinically and regulatorily anchored, scalable platform. This creates the prerequisites for strategic agreements and subsequent acquisition interest from globally operating companies that are already actively seeking similar platforms with a clearly defined clinical and regulatory trajectory and globally scalable potential.

Source: https://www.metro.cz/protext/zapominate-casto-a-vite-ze-to-muze-byt-predstupnem-alzheimerovy-demence.A260224_125000_metro-protext_air